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Research of medical gases is well established in Poland and has been marked with the foundation of several
professional societies. Numerous academic centers including those dealing with hyperbaric and diving
medicine conduct studies of medical gases, in vast majority supported with intramural funds. In general,
Polish research of medical gases is very much clinical in nature, covering new applications and safety of
medical gases in medicine; on the other hand there are several academic centers pursuing preclinical studies,
and elaborating basic theories of gas physiology and mathematical modeling of gas exchange. What
dominates is research dealing with oxygen and ozone as well as studies of anesthetic gases and their
applications. Finally, several research directions involving noble gas, hydrogen and hydrogen sulfide for cell
protection, only begin to gain recognition of basic scientists and clinicians. However, further developments
require more monetary spending on research and clinical testing as well as formation of new collective
bodies for coordinating efforts in this matter.
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This paper summarizes and critically reviews research
of medical gases in Poland done up to the year of
2012, predominately emphasizing interesting findings
and promising directions to follow. We have searched
bibliographical databases such as PubMed, MEDLINE,
SCOPUS, Web of Knowledge and also used Polish search
engines such as Expertus with publication records for em-
ployees of medical, agricultural, and military universities
and research institutes in Poland. Timeline of these
records stretched from April 1974 until January 2013.
Of note, search terms denoting Polish affiliations were
selected. In addition searching terms/phrases comprised
hyperbaric oxygen, oxygen, ozone hydrogen, hydrogen
sulfide, and carbon monoxide, nitric oxide, nitrous oxide,
halothane, enflurane, isoflurane, sevoflurane and desflurane,
and nitrogen. Then terms denoting noble gas were applied,
including but not limited to helium and xenon followed
by heliox and trimix, then pefluorocarbon and sulfur
hexafluoride, such as in Sonovue. In general we focused
on medical gases administered as exogenous agents, keeping
in mind though that some of these gases can be formed* Correspondence: rostrowski@imdik.pan.pl
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distribution, and reproduction in any mediumendogenously and partake in human physiology. A few
Polish review papers summarizing international research
of different gases in medicine, including those with
characteristics of gaseous transmitters, were included
here as well. On numerous occasions we refer to
original and review papers and commentaries written by
internationally renowned experts of the subject.On the historical note
One alchemist from Poland can be considered a father of
all Polish gas research. Michael Sendivogius, born in 1566
(died in 1636) studied philosophy, geometry, astronomy,
mechanics, and alchemy at Cracow Academy of Poland
and honed his skills at major European universities [1].
In 1604 he was able to obtain a gaseous substance that
he named “food of life”, from heating salpetre, some
170 years before a major discovery of oxygen by Priestley.
Apart from being an advisor to three Habsburg emperors -
Rudolph II, Matthias and Ferdinand II, Sendivogius
received hefty remunerations from the king of Poland
Sigismundus III Vasa who had a confidence in him, and
was an avid amateur alchemist himself.
During partitions of the country (since 1795) Polish
nationals worked in the gas research at the universities
annexed by Austria, Prussia, and Russia, producing great
results. Those include an invention of new methods ofCentral Ltd. This is an Open Access article distributed under the terms of the
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Olszewski and Zygmunt Wróblewski of the Jagiellonian
University in Cracow. They were able to liquefy these
gases first time in history from stable state air in 1883.
Later Wróblewski as first published the data on hydrogen’s
critical temperature, pressure, and boiling point (1885);
both liquid oxygen and nitrogen have widespread use in
medicine today [2-4]. In 1939, 21 years after regaining
independence by Poland, the Institute for Maritime
Medicine was erected in the coastal city of Gdynia which
had started an era of maritime, diving and hyperbaric
medicine. Since 1949 the Institute publishes a bulletin
currently known as “International Maritime Health”,
indexed in Medline. Currently the Institute is part of
Medical University of Gdańsk as Inter-Faculty Institute of
Maritime and Tropical Medicine [5]. It houses the
National Centre for Hyperbaric Medicine and DAN Europe
Office Polska located in Gdynia.
Polish research institutions conducting studies of medical
gases include hyperbaric medicine centers, universities
and institutes throughout the country.
Amongst organizations that nurture medical gas research,
are the Polish Society of Anaesthesiology and Intensive
Therapy issuing an official journal “Anaesthesiology
Intensive Therapy” established 1968, while the Polish
Hyperbaric Medicine and Technology Society, founded in
1997, since 2004 publishes “Polish Hyperbaric Research”
journal, formerly distributed in a bulletin form.
Oxygen in basic and clinical studies including hyperbaric
research
The major achievement of Polish scientists are testing
diagnostic applications of new parameters of oxygen physi-
ology, thereby contributions to its understanding. As far as
hyperbaric oxygen is concerned, Polish research not
only indicates efficacy and clinical safety of this therapy
in wound care and otorhinolaryngology, but novel
mechanisms of treatment as well. It needs to be stressed
however that interesting studies Polish of medical gas
for diving medicine requires separate review.
Thus, one Polish group created a system based on neural
network that can forecast arterial blood gas values com-
puted from several input parameters including hemoglobin
oxygen saturation [6]. Others elaborated purely mathemat-
ical model of oxygen gas exchange in the process of human
respiration, that allows to examine gas exchange upon
artificial oxygen ventilation and also to predict disturbances
of oxygen exchange in pathological settings [7]. Polish
scientists also adopted new oxygen status parameters
known from literature such as oxygen extraction tension
used e.g. to evaluate tissue hypoxia in diabetic children
and adolescents [8].
Therapeutic action of oxygen has been reported in several
studies advocating oxygen therapy at home, whichimproves life comfort and longevity of patients with
lung diseases [9]. However in the field of neonatology
it was found that oxygen increases the frequency of retin-
opathy of prematurity in neonates treated at FiO2 over 0.7
[10]. Another group has stated that oxygen should not ex-
ceed 40% during newborn resuscitation, and 100% oxygen
is allowed only transiently [11].
In Poland it was commander Augustyn Dolatkowski, the
first Polish member of Undersea & Hyperbaric Medical
Society, who pioneered in lobbying for introducing
hyperbaric oxygen into clinical practice. He postulated
establishing at least three hyperbaric oxygen treatment
centers, including one in district of Silesia, one in Warsaw
and one on the coast [12]. Around that time Poland
had operated oxygen chambers for patients in Sosnowiec
(1971), Warsaw (1973) and Gdynia (1974) [13]. At the
present time there are several more HBO chambers in the
country including at Siemianowice Śląskie (est. 2002),
Wrocław (2008), Łódź and Stalowa Wola (2009), and
those opened in 2012: in Łęczna (eastern Poland), and
another HBO center in Warsaw, run by a private clinic.
Clinical studies have shown that adjunct HBO, 10 × 2
ATA for 1 hour, is effective in the treatment of trophic
ulcerations from venous insufficiency [14]. Interestingly,
HBO at 2.5 ATA may improve thermoregulation by
rearranging microcirculation in trophic ulcerations of the
crura [15]. HBO administered within 2 to 60 exposures of
70 min. at 2.5 ATA was found to limit the extent of tissue
lesions and extent of amputations in diabetic foot patients
[16] [17]. In larger group of patients with thermal burns
HBO (2.5 ATA) reduced time to skin graft by 8 days,
decreased tissue edema, risk of respiratory failure, and
shortened duration of hospitalization [17]. HBO (2.5 ATA
for 90 min) also proved to be an effective therapeutic
adjuvant in Fournier’s gangrene, when given for seven
days twice a day [18]. In patients with electric burns
HBO (15–60 sessions) reduced infectious complications
and overall mortality [19]. HBO (20 to 40 expositions
per patient) cured postoperative sternal wound infection
and mediastinitis in 55 patient enrolled in the clinical study
[20]. Polish researchers as well found HBO beneficial
for bacterial and to a lesser degree fungal otitis (14 to 45
exposures at above parameters) [21]. In other series of
otorhinolaryngology cases HBO ameliorated hearing in
71% of patients under 18 treated for sudden sensori-
neural hearing loss; the authors used multiple HBO 2.5
ATA for 70 min. [22]. Furthermore, in adults 15 HBO
sessions at 250 kPa (100% O2) alleviated chronic severe
form of tinnitus compared to pharmacological therapy
alone [23].
HBO also appears to be an effective adjunct treatment
for radionecrotic type injuries including complications
of neck irradiation [24]. Using thermographic approach
others have found that HBO (30–60 × 90 minutes at 2.5
Ostrowski and Pucko Medical Gas Research 2013, 3:17 Page 3 of 10
http://www.medicalgasresearch.com/content/3/1/17ATA) increases blood supply and tissue metabolism in
cases of mandible osteoradionecrosis [25].
Polish preclinical HBO studies for neurological disorders
aim to verify the mechanism of treatment against complex
pathogenesis of neuron injury [26]. In one recent study
authors demonstrated that both HBO and HBA (2.5 ATA
for 60 min) increased neuronal survivability and functional
performance after 5 min global cerebral ischemia in gerbils.
Authors have postulated that equivalent reduction in cell
death in both treatment groups can be attributed to a
lowering effect of hyperbaria on brain temperature, regard-
less of air or oxygen [27]. The mechanisms of HBO have
been also studied in the neonatal rats subjected to 60 min
hypoxia-ischemia (HI). The authors demonstrated that
HBO administered at 2.5 ATA at 1 or 3 hrs after HI
reduced SOD activity in cerebral tissues while increasing
GSH content and that HBO reduced brain damage
more effectively than HBA treatment. Authors suggested
that the production of free radicals was reduced with
HBO and HBA, which manifested itself in decreased
SOD activity [28]. When analyzing hypobaric hypoxia
postconditioning the authors have found increased
SOD activity and control GSH levels, which points towards
distinctive molecular mechanisms triggered by each of the
conditionining means.
Ozone therapy
The major achievement of Polish ozone studies was to add
novel clinical data allowing to broaden ozone indications
in the clinical management of orthopedic surgery and
dentistry, and demonstrate the application of ozone treat-
ment in toxicology. In addition Polish researchers indicated
which bacterial species are particularly susceptible to ozone
therapy for dental care.
Similar to HBO, ozone inhibits septic processes in the
wounds and facilitates wound healing; and it is believed
that devising new methods of ozone administration may
optimize those effects [29]. In this regard ozone was found
to be prophylactic against septic complications in total hip
plasty with and without cement [30]. Ozone administration
was associated with completely cured bedsores in 16% of
patients while in further 20% patients a significant improve-
ment was noted as compared to the control group with
traditional treatment [31]. As to lower extremities ailments
ozone femoral artery injections administered for the
treatment of atherosclerotic ischemia of the lower extrem-
ities more than doubled claudication distance [32]. More-
over, ozonated autohemotherapy (50 ug/ml) stimulated
potentially beneficial changes in serum lipids including
a decrease of total cholesterol and LDL levels in athero-
sclerotic ischemia of lower limbs [33]. Ozone (60 μg
O3/mL i.v.) also normalized the activities of arylsulphatase,
cathepsin D, acid phosphatase, and alpha-1-antitrypsin
blood levels in patients with obliterative atheromatosis[34]. In gonarthrosis patients addition of ozone at 64 μg/m3
(0,032 ppm) in bath to the routine therapy reduced inci-
dence of pain and diminished the use of analgesics [35].
Polish dental studies revealed that ozone kills number
of viruses including HV1, HV2, and bacteria including
Actinobacillus actinomycetemcomitans and Campylobacter
gracilis and sputorum of the mouth and oral cavity; the
bactericidal effects manifested themselves at 3,0 or 3,4 μg/
mL ozone for 50–60 s [36,37]. Others have demonstrated
potent oxidative effect of ozone towards Streptococcus,
Staphylococcus and Enterococcus species isolated from the
oral cavity [38]. While, ozone also decreases Fusobacterium
nucleatum in gingival pockets [39]. The intracanal applica-
tion of ozone proved to decrease periapical inflammation
and caused absence of pain or exudate in root canal
(HealOzone device, KaVo Co. up to 2100 ppm) [40].
Studies in 131 young patients age 11–12 revealed usefulness
of ozone stopping progression of occlusal pit and fissure
caries of premolar teeth with use of the device as above
[41]. Moreover, in patients aged 21 till 65 ozone treatment
was proposed for dentin hypersensitivity as a clinical
method of eradicating bacteria from dentinal tubules
thus facilitating beneficial penetration of fluoride, calcium,
phosphates and tin minerals into the tooth in treatment
(Heal Ozone, KaVo) [42].
On the other hand several Polish studies indicate a
need for close monitoring over biochemical and prote-
omic indices of ozone therapy as it proved to have a de-
composing impact on serum tocopherols (40–45 μl per
1 cm3 oxygen-ozone mixture in isotonic salt solution drip)
[43], and oxidized blood lipids (30 μg/mL) [44]. Ozone
however may have a therapeutic potential in toxicology;
oxygen-ozone mixture injections reduced metallothionein
level and cadmium accumulation in rat kidney after
cadmium acetate intoxication [45]. An early bird for
investigation of molecular mechanisms of ozone therapy
was the proteomic study of ozonated blood by Ciborowski
et al. [44]. The products of ozonation including ROS,
H2O2 and LOPs play not only a role of biomarkers but are
mediators of subcellular mechanisms of ozone treatment.
Hydrogen peroxide activates tyrosine kinase which phos-
phorylates NF-κB fighting immune depression. Ozone
generates LOPs which unlike ROS are longer lasting and
activate endothelial cells leading to increased production
of NO and vasodilatation, while may mediate bone
marrow stem cells’ mobilization as well [46].Nitric oxide, carbon monoxide and hydrogen sulfide:
gas giants and hot research spots
Nitric oxide, carbon monoxide and hydrogen sulfide belong
to the gaseous transmitters. The gases in this group can
be used therapeutically although except nitric oxide, have
mostly investigational status at this point.
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Polish researchers was to add new data on the clinical
management of pulmonary hypertension and demonstrate
its role oxide as gastroprotectant, and the involvement in
nociception.
Inhalational nitric oxide has been a matter of investiga-
tion in cardiology of the adults and infants [47]. Patients
with mitral valve and pulmonary hypertension inhaling
NO (30 ppm) for 15 minutes before cardiac surgery pro-
cedures demonstrated favorable acute circulatory reaction,
especially a reduction in pulmonary resistance [48]. Nitric
oxide (8,15 ± 5,73 ppm) when inhaled upon imminent
pulmonary hypertensive crisis after open heart correction
in children caused a positive hemodynamic response
manifested as reduced pulmonary arterial pressure and
increased PaO2 [49]. Indeed nitric oxide causes pulmonary
arteries to display their vasodilatatory reserve as in cases
of dilated cardiomyopathy [50].
Another research approach relies on the compounds
releasing NO or triggering its production. Donors of NO,
such as 3-morpholinosyndnoimine, S-nitroso-N-acetyl-
DLpenicillamine, nitroglycerin and NO-aspirin have been
demonstrated to act as gastroprotectants upon water
immersion restraint stress [51]. Polish researchers found
that NO mediated ulcer healing imparted by cholecysto-
kinin [52]. In addition, endogenous NO has been found
involved with the mechanisms of gastric preconditioning
by means of 5 minute celiac artery occlusion [53]. It seems
that the mechanism of NO mediated preconditioning can
be similar to the one found in cardiac preconditioning and
involve NOS, soluble guanyl cyclase and protein kinase G.
Signal could be further transmitted to mitochondria via
the opening of ATP-sensitive K+ channel and inhibition
of the mitochondrial permeability transition pore in
mucosal cells [54].
As to nociceptive action of NO, its endogenous donor
L-arginine decreased antinociception effect of diazepam,
chlordiazepoxide or clonazepam on the writhing test in
mice consistent with the notion that excess NO produces
hyperalgesia [55]. Additionally on the formalin test in rats,
NO decreased spinal antinociceptive effect of clonidine
but not that of baclofen [56].
Polish studies have also indicated benefits of carbon
monoxide in organ transplant and preconditioning, beside
studying mechanisms of toxicity upon excess CO [57].
One study has suggested that CO may be involved with the
mechanisms of preconditioning, prior to organ transplant.
The authors evaluated kidney transplant from CO poisoned
donor and found prolonged tolerance of kidney to ischemia
(total ischemia time was 24 hours and 35 minutes), effect-
ive urine production and uneventful clinical post transplant
course. They postulated that CO may be responsible
for preconditioning effect in clinical transplantation
procedures, possibly due to anti-ischemic and anti-inflammatory properties of CO [58]. Indeed, CO was
found to combat sepsis, mediate anti inflammatory effect
in the liver and protects against renal ischemia-reperfusion
injury [59]. Of note CO donor administration can inhibit
thrombosis, through a decrease in active plasminogen
activator inhibitor-1 or a decrease in fibrin generation,
independently of guanyl cyclase (as in case of NO), which
may prove beneficial with respect to organ transplant [60].
As reviewed by Amano et al. molecular mechanism of
CO at therapeutic doses may involve modulating immune
response in graft donors, in particular diminishing expres-
sion of MHC class II on dendritic cells and reducing
APC –induced T cell proliferation, TNF-α and IFN-γ,
and IL-2 production [61]. Furthermore CO increases
HIF-1α and VEGF expression as well as bcl-2 production
leading to reduced apoptosis.
H2S is a gaseous neurotransmitter involved with long-
term potentiation and smooth muscle relaxation [62]. In
the living organisms H2S forms an aqueous solution of
weak acid or is present as an anion. Although administra-
tion of gaseous H2S has been used in research, its proper
dosage appears challenging (usual range 20-80 ppm) [63].
In the field of hydrogen sulfide studies Wiliński and
colleagues at the Jagiellonian University have shown
the immense impact of a variety of pharmacological
agents on endogenous H2S production and postulated
the pharmacomodulatory role of H2S in this setting
[64]. According to their investigations Vitamin D3 at
doses up to 40000 UI/kg b.w. increased tissue free H2S
concentration in the heart (by 74.1%) and to a lesser
degree in the brains and kidneys of male SJL mice [65].
The authors further demonstrated that other repeatedly
administered drugs, including aspirine, acetaminophen,
atorvastatin, ramipril, amlodipine, digoxin and and carve-
dilol, affect sulfur metabolism and H2S [65]. Interestingly
they found that aspirin (10 mg/kg b.w.) decreased H2S
levels in the brain of female albino Swiss mice (although
increased in the liver) contrary to some other reports
showing aspirin-induced H2S elevation in female BALB/c
and male B10.PL mice. Therefore, they postulated that
H2S production in mouse brain could be strain dependent
[66]. Acetaminophen (30 mg/kg b.w.) produced marked
increase in H2S tissue concentration in the heart and
kidney while decreased its levels in brains of female CBA
mice [67]. In same strain of mice the effect of atorvastatin
injected at a dose of 5 or 20 mg/kg, remarkably increased
H2S concentration in the kidney, and also in the brain and
heart at a dose of 5mg/kg, while decreased in the liver at
both doses [68]. In CBA mice of both sexes, Ramipril, 5 or
10 mg/kg increased H2S tissue concentration in mouse
liver while decreased in kidney, where H2S by itself has
been identified as inhibiting ACE [64]. Experiments with
cardiological medications showed that carvedilol at high
doses increased tissue H2S level in the heart (by 75%)
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female mice. Digoxin increased H2S in all investigated
organs (BALB/c male mice), especially in the heart (by 22%)
while amlodipine tended to decrease it in all examined
organs (CBA mice) [69-71]. Overall these findings further
implicate the H2S in the nociception, NO and CO metab-
olism, ACE regulation, and cardioprotection, however,
with little indication as to the molecular mechanisms
downstream of H2S. Studies by Calvert et al. have shown
that H2S is a potent inducer of Nrf2 which governs a
group of antioxidant and drug metabolizing genes [72].
How Nrf2 activation relates to findings by Wilinski et al.
awaits further investigation.
Above mentioned gaseous compounds have been pro-
posed as therapeutic agents, e.g. the administration of H2S
donors for renal diseases, associated with deficiency of
endogenous H2S [73]. Since NO can increase red blood
cell deformability, its donors have been proposed as
agents improving blood fluidity [74]. However any carbon
monoxide treatment due to a risk of toxicity would need
to be closely monitored [75].
Volatile anesthetics in basic and clinical research
Polish researchers made valuable contributions to pros
and cons discussion over advantages of intravenous vs.
inhalational anesthesia. They increased overall number
of clinical cases examined in the world literature in order
to establish superiority of anesthetic methods in this
regard. The achievement worth emphasizing was also
to demonstrate the involvement of endogenous opioids
in the mechanisms of volatile anesthesia/analgesia. The
work by Polish researchers on EEG pattern analysis
furthered the understanding of mechanisms behind
inhalational anesthesia. Time will tell whether new algo-
rithms of EEG analysis elaborated in Poland will be
broadly implemented for anesthesiological procedures.
The Polish researchers were also amongst the first
to show advantages of newer halogenated gases over
older agents e.g. they showed that isoflurane has lower
genotoxicity than halothane towards peripheral blood
lymphocytes [76]. Other authors demonstrated that
compared to isoflurane, enflurane produces stronger
alterations in the activities of brain enzymes responsible
for catabolic processes, and the rates of exchange and
transport of energetic substrates in the striatum and
hypothalamus in the rabbit brain. Therefore, the authors
suggested that enflurane offers lower safety than isoflurane
[77]. Polish authors also conducted the comparisons
between different 3rd generation agents e.g. sevoflurane
and isoflurane (0.6-1.5 MAC) for cardiopulmonary bypass,
by assessing total usage of phenylephrin administered
against drops in arterial pressure, which together with
hemodynamics data revealed no difference in major
parameters including cardiopulmonary bypass and aorticcross clamp times, ejection fraction, temperature, and
EuroSCORE indexes. [78]. Researchers at Medical Univer-
sity of Lublin found that desflurane increased peripheral
perfusion in elective gynecologic surgery patients as
determined with perfusion index [79]. The classic advan-
tage of desflurane, rapid emergence from anesthesia, was
studied in obese patients by Dr. Gaszynski who found
faster recovery and faster (16,3 vs 22,4 min) reaching 10
points on the Aldrete scale by those patients (47 individuals
with BMI >40 kg/m2; ASA 2) anesthetized with desflurane
for gastric banding, compared with sevoflurane [80]. Inter-
estingly, sevoflurane anesthesia can reduce rocuronium
requirement as sevoflurane potentiates neuromuscular
block [81]. Similarly sevoflurane decreased the required dose
of muscle relaxant in laparoscopic gastric banding [82].
Other comparisons were made between halogenated
anesthetics such as isoflurane and injectable anesthetics
e.g. propofol. Both isoflurane and propofol provided
effective clinical anesthesia and could be safely used
for short gynecological surgery. Times to eye opening, to
recovery of spontaneous breathing, and to extubation were
equivalent between inhalation and injection anesthesia
groups [83]. Similarly, single-breath vital capacity rapid in-
duction with 8% sevoflurane followed by 1.5% sevoflurane
with N2O was as effective as propofol for short gyne-
cological procedures [84]. Desflurane and propofol com-
bined with thoracic epidural anesthesia showed similar
effectiveness and safety profile in one lung ventilation
upon lobectomy [85]. As demonstrated in patients with
embolization of cerebral haemangiomas or arteriovenous
malformations, sevoflurane provides safe and stable anes-
thesia for interventional neuroradiological procedures
compared to propofol/fentanyl anesthesia [86].
However quite a few Polish studies investigated the
very mechanism of anesthetic action of halogenated gases
both on basic science and clinical grounds where the
understanding is far from complete. These studies showed
that once postulated theory of anesthesia, referring to
endogenous opioid peptides may appear plausible as
leu-enkephalin has been found increased in hypothalamus,
hippocampus, mesencephalon and lumbar segment of
spinal cord in isoflurane anesthetized rabbits. However
both leu-enkephalin and met-enkephalin decreased in
the cervical segment while met-enkephalin content dropped
in thoracic part of the spinal cord. Unlike isoflurane
halothane decreased leu-enkephalin content in the hypo-
thalamus, while increased in the hippocampus. Methionine-
enkephalin levels however increased upon halothane
and persisted at least 1 hr after anesthesia has been
ceased [87,88].
Polish researchers actively participate in devising new
analysis modes for investigating mechanisms and safety
of volatile anesthetics. BIS monitoring is commonly used for
studies aimed at optimization of anesthesia for particular
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e.g. that desflurane allows to wake faster, when compared
with sevoflurane and isoflurane, after lumbar laminotomy
in 60 adult patients [89]. One Silesian group studied EEG
propagation under sevoflurane using directed transfer
function method. Indeed the assessment of propagation
directions of EEG signals between channels may upgrade
analysis of spatial distribution of EEG activity [90].
Furthermore, quantitative analysis of EEG for transition
from consciousness to unconsciousness for isoflurane,
sevoflurane and desflurane revealed relative powers of
particular EEG waves [91]. As to desflurane, researchers
further elaborated new methods to detect sharp wave and
slow wave components of the EEG pattern to investigate
of possible side effects of this anesthetic gas in the clinical
settings [92].
Notably the impact of inhalational anesthetic agents
on body systems/organs has been studied in Poland as
well. Studies have indicated that sevoflurane low flow
(0.8–1 L min–1) air-oxygen-sevoflurane (1–3 MAC)
does not increase nephrotoxicity of chemotherapeutic
agents [93]. It also turned out that both isoflurane and
halothane could affect airway transepithelial potential
difference in the isolated rabbit tracheal wall, which
suggests depressing airway clearance. Notably, isoflurane
distinctly less affected the depolarization component
while the reaction to both gases was fully reversible
[94]. In the meantime studies directed at risk of toxicity
turned out quite favorable for sevoflurane, which did
not induce any increase in DNA migration in blood lym-
phocytes proliferating in vitro, in contrast to halothane
and isoflurane [95]. However sevoflurane’s impact on liver
function has been reconfirmed. Sevoflurane was found
to be a more potent microsome liver cytochrome b5
inhibitor than desflurane [96].
Then the mechanisms of brain and heart protection
with volatile anesthetic agents gained Polish researchers’
interest as well. As stressed in one original paper by
Baranowska et al. neurological complication during heart
surgery relate to long duration of ventilation, prolonged
crossclamping and CPB while low CPP, history of atrial
fibrillation or stroke as well as advanced age, hence the
need for clinically effective preconditioning procedures
[97]. Both isoflurane and sevoflurane could reduce
biochemical markers of brain injury including MMP-9,
GFAP and S-100β, and ameliorated disturbed arterioven-
ous magnesium concentration differences in patients after
CABG, as compared to intravenous anesthesia [98,99].
Studies conducted in USA and elsewhere have shown
multiple mechanisms for brain protection with isoflurane
including activation of ATP-regulated potassium channels,
upregulation of NOS and PI3K-AKTand reduced excitotoxic
stress [100]. Recent studies have indicated that major
mechanism of isoflurane-induced neuroprotection leadsthrough sphingosine-1-phosphate/phosphatidylinositol-3-
kinase/Akt pathway [101].
In addition, Polish experimental studies have shown
that sevoflurane inhibits synthesis and release of excitatory
neurotransmitters, including glutamate, and inhibits
activation of microglia and astrocytes responsible for the
occurrence of inflammation after ICH [102,103].
Some Polish researchers have examined volatile anesthesia
against cardiac injury as well. One study has found that
anesthetic preconditioning with sevoflurane (20 minutes
of sevoflurane 2 vol% inhalation at 10 min prior to
CABG under CPB) acutely activates ROS generation in
coronary sinus blood, but then decreases blood levels of
interleukin-6 at six hours after surgery [104].
Particularly interesting direction in research is formed by
nitrous oxide studies. N2O is commonly used to decrease
anesthetic requirements of halogenated gases allowing to
study different anesthetic agents at lower concentrations.
Upon such studies Polish researchers found that children
anesthetized with N2O/O2–fentanyl had higher mivacurium
requirement than those in halogenated anesthetics/N2O/O2
group, which may carry implications for residual muscle
weakness [105]. The duration of intubating dose and
spontaneous recovery of neuromuscular transmission were
significantly prolonged by halogenated gases as compared
to N2O/O2 –fentanyl anesthesia [106].
Also, encouraging results were reported for nitrous
oxide in sedation. Some Polish authors postulated that
nitrous oxide should be wider used for sedation in oral
surgery [107]. One study has found however that despite
good outcomes of nitrous oxide sedation for dental treat-
ment 6 out of 20 children refused to breathe through the
mask under any circumstances and had to be subjected to
general anesthesia [108]. Definitely, caution should be
advocated for the use of N2O or halogenated anesthetics
in sedation especially in children as there is a substantial
body of data pointing towards possible neurodegenerative
effects of those in case of prolonged exposure [109].
Noble gas in Polish medical research
Amongst noble gases helium has been studied quite
extensively in the intensive care and diving medicine in
Poland. Polish scientists contributed to establishing
usefulness of breathing helium for diving and treatment of
diving accidents, and used against neonatal respiratory
distress as well. These series of diving cases are of unique
value, especially diving accidents cannot be easily replicated.
Helium neonatal studies also have a great importance for
clinical practice. These have proved that medical gas
research conducted in Poland can advance to clinical
trials registered with NIH.
Helium in diver’s breathing gas allows to decrease
partial pressure of nitrogen thus diminishing unfavorable
effects of the latter, helium also allows to decrease the
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helium and oxygen, has been proposed to counter
unfavorable hematological consequences of diving, amongst
which loss of circulating platelets appears most common
[110]. With this regard, breathing trimix (O2 – 18.5%,
N2 - 44%, He – 37.5%) prevented reduction in the number
of platelets and loss of coagulation factor XII in male
professional divers subjected to 0.7 MPa exposure (35 min.
plateau). Since solubility and diffusion coefficients of helium
are relatively low there will be faster release of dissolved
gas during decompression and reduced formation of gas
bubbles in diver’s blood, hence reduced number of platelet
aggregates [111].
Breathing gas mix with helium has been investigated
clinically as well. As reviewed by Polish authors, heliox,
possess suitable properties as a carrier of aerosol therapy
and a breathing mix upon mechanical ventilation. These
include facilitation of laminar flow and reduction of airway
resistance. Therefore it has been postulated that patients
with severe bronchospastic diseases may experience the
greatest benefits of breathing heliox [112]. Others have
postulated that heliox containing 20% oxygen and 80%
helium seems to be a very promising treatment in the
management of the acute phase of severe respiratory
disturbances in the newborn [113]. A group of researchers
at Poznań University of Medical Sciences administered
heliox through mechanical ventilation in the meconium
aspiration syndrome in neonates. This particular study
was a subject to a clinical trial registered at http://
clinicaltrials.gov. Recently the authors have reported
that there was a significant increase in the PaO(2)FiO(2)
ratio during heliox ventilation in their clinical setting
[114]. As to moleculaer mechanisms helium imparts influ-
ence on molecular machinery of the cells within lungs, the
immune system, and the blood, besides improving work of
breathing. At least part of therapeutic effects of helium
may be ascribed to activation of mitochondrial ATP
regulated potassium channels for cell protection [115].
On some gaseous compounds for ultrasonography
It is an important contribution of Polish researchers to
prove safety of ultrasound sulfur hexafluoride microbubble
contrast agent (SonoVue) with respect to hematologic
system. Furthermore, based on extensive research Polish
authors postulated that contrast enhanced ultrasound
may become a method of choice for determination of
character of liver lesion.
Micro bubble contrast agents, formulated with encap-
sulated gaseous compounds, have received researchers
attention for the studies of contrast enhanced ultrasound
(CEUS). In the beginning ultrasound contrast agents
utilized air microbubbles (generated via sonication) or
galactose microparticles [116]. Later on, many studies
have investigated the ultrasound second-generationcontrast agents such as SonoVue. This particular agent is
formed by stabilized microbubbles of sulfur hexafluoride
(SF6) gas and exhibits an outstanding safety profile [117].
Bubbles of SF6 are extremely small; the bubble diameter
in SonoVue averages 2.5 μl, which allows to minimize
total volume of injected gas [118]. Polish researchers
elaborated on SonoVue safety by demonstrating with
electrophoretic mobility techniques that SonoVue did
not produce large changes with respect to surface charge
density of red blood cell membranes [119]. Based on the
results obtained in Polish academic hospitals contrast
enhanced ultrasound has been postulated as a modality of
choice in the diagnostics and differentiation of benign
focal liver lesions [120]. Although being less accurate
than histological assessment CEUS still allows to predict
malignant character of renal lesions [121]. CEUS has been
also compared to CT with respect to accuracy of imaging.
Contrast-enhanced ultrasonography may be considered an
alternative technique to CTA in monitoring patients after
abdominal aortic aneurysm repair [122]. There was a high
accordance between CEUS and CT in the diagnostics of
metastatic liver lesions [123]. In cases of liver hemangiomas
CEUS managed to approximate CT accuracy, however spe-
cificity and negative predictive value appeared lower [124].
Concluding remarks and prospects of researching medical
gases in Poland
In summary research of medical gas in Poland is in large
part directed at testing novel clinical applications of
medical gases. However thorough investigations with the
use of molecular biology and genetics techniques, including
omics approach, are developing as well. Undeniably, in
order to progress, research of medical gas needs to be
financed from major dedicated funds. This appears
necessary, especially to assure diversity in translational
research, but also to integrate medical gas research
with stem cell and molecular biology investigations. Also,
to further medical gas research in Poland, international
collaborations with leading medical gas research centers
are warranted, for mutual benefits.
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